Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Although TNF-alpha inhibitors remain the preferred choice for psoriatic arthritis (PsA) treatment following conventional DMARDs, the more recently introduced IL-17 inhibitors, Cosentyx and Taltz, and the oral therapies Otezla and Xeljanz have chipped away at the TNF inhibitors’ patient share. Understanding the unmet need in the treatment of PsA and the factors that can differentiate similar products from one another can determine the success of an agent in this competitive space. This report discusses the unmet needs associated with PsA treatment, based on the perceptions of U.S. and European rheumatologists, and which emerging therapies, if any, can capitalize on these opportunities.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in February 2019
Key companies: AbbVie, Amgen, Janssen, Celgene, Novartis, Pfizer
Key drugs: Adalimumab, etanercept, infliximab, ustekinumab, apremilast, secukinumab, tofacitinib
Already a Client? Log in to access this report.
Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.